<u>Cite this as</u>: He HUANG, Heng-wei WU, Yong-xian HU, 2020. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. Journal of Zhejiang University-Science B (Biomedicine & Biotechnology), 21(1):29-41.

https://doi.org/10.1631/jzus.B1900351

Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma

Key words: Chimeric antigen receptor (CAR) T cells,
Immunotherapy, Monoclonal antibody (mAb), Target
antigen, Multiple myeloma

Research Summary

This review focused on current advances in chimeric antigen receptor T cell therapy for refractory/relapsed multiple myeloma in following aspects:

- candidate antigens
- adverse effects & management strategies

• Introduction of multiple myeloma, the basic structure of CAR T cell and the history of CAR T therapy.

• Innvoation of promising antigens are being actively investigated.

• Attention to the adverse effects of CAR T therapy and provide viable management.

